Abstract
The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of
4.9% for the period 2006-2012. The ED market contains three leading drugs
Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most
popular and recognised brand on the market. Furthermore, high revenues are
predicted by visiongain for the top three ED drugs, with Cialis reaching
blockbuster status by 2007. This detailed report also highlights pipeline
developments and important contemporary issues, especially commercial drivers
and restraints. The purpose of this market analysis by visiongain is to
examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022,
including sales forecasts for leading pharmaceutical products.
Most men experience ED at some points in their lives usually by the age of 40,
but are not necessarily psychologically affected by it. Some men, however,
experience chronic and complete ED. Over 150 million men worldwide are unable
to achieve and maintain an erection adequate for satisfactory sexual
intercourse; visiongain expects this figure to double by 2020. Despite its
commonplace occurrence, ED is a notoriously under-reported, under-recognised,
and an under-treated chronic illness. It is estimated that 85% to 90% of all
ED goes undiagnosed.
The ED Market Report examines the market critically through a comprehensive
review of available information. Sources include industrial databases,
commercial news, published reports, economic research and consultation with
experts. Visiongain applies financial forecasting, qualitative analyses and
the assessment of unmet needs to provide a comprehensive market report with
detailed analysis and informed opinion.
In particular, The ED Market concentrates on the following essential aspects of the market:
- Discussion of the current pharmaceutical market
- Forecast of the worldwide pharmaceutical market from 2007-2012
- Drivers and restraints facing the ED market
- Opportunities and threats facing the ED market
- Growth of the ED drugs market between 2007-2012
- Commercial prospects for the market-leading drugs, with sales forecasts
from 2007-2012
- The potential of generics manufacturers to penetrate this market
- Pipeline developments with blockbuster potential
- Currently marketed drugs with blockbuster potential
- Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for ED drugs from
2007-2012
- To discover predicted revenues, growth rates and other key metrics for
leading pharmaceutical treatments from 2007-2012
- To determine key activities of leading companies
- To discover "hot" pipeline developments and up-and-coming products
- To determine the forces that influence the market for ED products:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats (SWOT analysis)
- To find out where the ED market is heading - both technologically and
commercially
Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and
present developments in the ED Market. Amongst the catalogue of products in
the ED pipeline is transdermal therapies. Neew innovative products for ED has
generated a high level of interest from; top-tier companies, the major players
in the ED circle and niche companies alike.
This visiongain report is the single tool to equip you with the latest trends
in all regional markets and why drug companies are aiming for a new generation
of drugs. Visiongain recommends this astute report to the major players in the
field as it will arm you with the clinical challenges that larger companies
face to date, thus the rising inherent cost of R&D expenditure to in order
meet the requirements set by major regulatory authorities for larger evidence
of clinical data before any authorisation.
The ED Market Assessment & Analysis 2007-2022 report is a must buy, because it
presents in-depth and unbiased financial analysis for the near-term,
medium-term and the long-term, market dynamics.
Unique benefits to you when you order this report:
- - Primary research throughout. You will not find this information anywhere
else
- - Report stored in your reading room for ever
- - Full searchable report when you buy the company or corporate editions
- - Copies can be printed off for offline reading
- - Packed with charts, analysis, figures, graphs and tables
View Cart
